NCT06543303: An ongoing trial by BioTheraVision, Inc.
This trial is ongoing. It must report results 10 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06543303 |
|---|---|
| Title | A Phase 2, Double-Masked, Randomized, Vehicle-controlled Trial Evaluating the Efficacy and Safety of Cevimeline Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 31, 2024 |
| Completion date | Feb. 15, 2026 |
| Required reporting date | Feb. 15, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |